H-021 / Carephar Pharma - LARVOL DELTA

A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - P2 | N=156 | Not yet recruiting | Sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd.

New P2 trial • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL23A

An open-label, single-sequence, two-period crossover comparative bioavailability study of H021 tablets (ChiCTR) - P1 | N=10 | Sponsor: Shulan (Hangzhou) Hospital; Shulan (Hangzhou) Hospital

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A random, open, two-sequence, two-period crossover design was used to evaluate the food effects of H021 tablets in a clinical study. (ChiCTR) - P1 | N=12 | Sponsor: Shulan (Hangzhou) Hospital; Shulan (Hangzhou) Hospital

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Evaluation of the tolerability, safety and preliminary efficacy of H021 tablets in patients with ulcerative colitis: a multicenter, open, single-arm phase Ic clinical trial (ChiCTR) - P1 | N=8 | Not yet recruiting | Sponsor: Gansu province people hospital; Jiangsu Carephar Pharmaceutical Co., Ltd

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Randomized, Double-Blind, Placebo-Controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Multiple Doses of H021 Tablets in Healthy Adult Subjects (ChiCTR) - P1 | N=10 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Soochow University; Jiangsu Carephar Pharmaceutical Co., Ltd

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis